Achieving Durable Clinical Response with Targeted Treatment for Vitiligo


In this MEDcast episode, Dr Chovatiya and Dr Bunick delve into the advancements in targeted treatments for vitiligo, exploring their potential to provide long-term efficacy and durable clinical response.

0:53 Quality of life impact of vitiligo

2:55 Pathogenesis of vitiligo

5:08 Approaches to vitiligo treatment

8:30 Mechanism of JAK inhibitors

10:25 TRuE-V1 and TRuE-V2 studies for the JAK inhibitor ruxolitinib

14:15 Variation in repigmentation with vitiligo

17:20 Safety of topical ruxolitinib

21:00 Data from the long-term extension trial of ruxolitinib

25:75 Achieving meaningful treatment response in vitiligo

30:15 Investigational biomarkers and treatments for vitiligo

Related Videos
Hong-Uyen Hua, MD; Sruthi Arepalli, MD; and Peter Kaiser, MD
Connective Tissue Disease Brings Dermatology & Rheumatology Together
Kelly Nichols, OD; Laura Periman, MD; and Mile Brujic, OD
What Makes JAK Inhibitors Safe in Dermatology
Potential JAK Inhibitor Combination Regimens in Dermatology
Therapies in Development for Hidradenitis Suppurativa
"Prednisone without Side Effects": The JAK Inhibitor Ceiling in Dermatology
Discussing Changes to Atopic Dermatitis Guidelines, with Robert Sidbury, MD, MPH
How Will Upadacitinib, Povorcitinib Benefit Hidradenitis Suppurativa?
The JAK Inhibitor Safety Conversation
© 2024 MJH Life Sciences

All rights reserved.